格隆汇1月12日丨先声药业(02096.HK)公告，1月12日耗资4194.5万港元回购367.2万股。 ...

智通财经APP讯，先声药业(02096)发布公告,于2026年1月12日，该公司斥资4194.53万港元回购367.2万 股股份，每股回购价11.1975-11.6港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 先聲藥業集團有限公司 (於香港註冊成立之有限公司) 呈交日期： 2026年1月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02096 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前 ...

Major Events - CATL (03750) plans to issue an additional 34.8584 million shares [1] - MINIMAX-WP (00100) fully exercised its over-allotment option involving a total of 4.3796 million shares [1] - MIRXES-B (02629) established a strategic partnership with N Health, and its HELICORapid and FITRapid home testing kits received regulatory approval [1] - LFG Investment Holdings (03938) was acquired by Chen Shaoyang, who purchased approximately 61.43% of shares at a discount of about 59.46% through a cash offer, with resumption of trading on January 12 [1] - Xiansheng Pharmaceutical (02096) plans to spin off its H-shares for independent listing on the main board of the Hong Kong Stock Exchange [1] - OmniVision Technologies (00501) saw its public offering in Hong Kong oversubscribed by 9.28 times, with a share price of HKD 104.8 [1] - China Nonferrous Mining (01258) released its production guidance for 2026, expecting a total copper output of approximately 484,000 tons [1] - China Rare Earth Holdings (03788) reported a 53.1% increase in JORC ore reserves to 2.62 million ounces, with JORC gold resources rising to 5.54 million ounces [1] - Black Sesame Intelligence (02533) plans to issue a total of 30.1319 million subscription shares, raising approximately HKD 568 million [1] - Shanghai Pharmaceuticals (02607) received approval for the production of bromhexine oral solution [1] - Beijing Energy International (00686) signed an EPC contract for a 100 MW wind power project in Heilongjiang Province [1] - Standard Chartered Group (02888) plans to issue SGD 750 million fixed-rate reset perpetual subordinated convertible securities [1] Share Buybacks/Reductions - Geely Automobile (00175) repurchased 1.547 million shares for HKD 26.6229 million on January 9 [2] - Sunny Optical Technology (02382) repurchased 840,000 shares for HKD 53.9894 million on January 9 [2] - Xiaomi Group-W (01810) repurchased 4 million shares for HKD 151 million on January 9 [2] Operating Performance - China Jinmao (00817) achieved a cumulative contracted sales amount of RMB 113.5 billion for 2025, a year-on-year increase of 15.52% [2] - Jiumaojiu (09922) reported stable performance for its main brands in the fourth quarter [2] - CIFI Holdings Group (00884) recorded a cumulative contract sales amount of approximately RMB 16.1 billion for 2025 [2] - R&F Properties (02777) reported total sales revenue of approximately RMB 14.21 billion for 2025, a year-on-year increase of 26.54% [2] - Zhongliang Holdings (02772) reported a cumulative contract sales amount of approximately RMB 12.07 billion for 2025, a year-on-year decrease of 32.68% [2] - Shui On Land (00272) achieved a cumulative contract property sales amount of RMB 7.916 billion for 2025 [2] Additional Performance Metrics - Greenland Hong Kong (00337) reported contract sales of approximately RMB 7.214 billion for 2025, a year-on-year decrease of 21.66% [3] - Yuzhou Group (01628) achieved a cumulative sales amount of RMB 6.727 billion for 2025 [3] - New World Development (01030) reported contract sales of approximately RMB 1.354 billion in December [3] - China Shipbuilding Defense (00317) expects a year-on-year increase of 149.61% to 196.88% in net profit attributable to shareholders for 2025 [3] - Longyuan Power (00916) completed a cumulative power generation of 76.4694 million MWh for 2025, a year-on-year increase of 1.22% [3] - Sunny Optical Technology (02382) reported a December shipment of 95.592 million mobile phone lenses, a year-on-year decrease of 8.9% [3] - COFCO Joycome (01610) reported a December pig output of 567,000 heads, a month-on-month increase of 1.43% [3] - Dekang Agriculture (02419) sold 1.1097 million pigs in December, generating sales revenue of RMB 1.664 billion [3] - Hengding Industrial (01393) reported a coal output of 5.415 million tons for 2025, a year-on-year increase of 31% [3] - Orient Overseas International (00316) reported a 17.2% decrease in quarterly shipping revenue compared to the same period last year, with total cargo volume up 0.8% and carrying capacity up 4.5% [3]

待建议分拆及建议上市完成后，本公司预期将拥有先声再明超过50%的权益，而先声再明将仍然为本公 司的附属公司。 先声再明为一家处于全球药物创新前沿的生物制药企业，聚焦于肿瘤创新药物的研究、开发与商业化 (不包括与细胞疗法及基因诊断与治疗技术相关的药物)。 先声药业(02096)发布公告，本公司建议分拆本公司附属公司先声再明的H股在联交所主板独立上市。先 声再明H股于联交所主板独立上市构成本公司根据第15项应用指引分拆先声再明。联交所已确认本公司 可进行建议分拆。 于2026年1月9日，先声再明就申请先声再明H股于联交所主板上市及获准买卖，向联交所递交上市申请 表格(A1表格)。按照计划，先声再明将就建议上市进行新股发售。受限于若干条件，合资格股东将可透 过在全球发售项下优先申请先声再明H股的方式，而获提供先声再明H股的保证配额。 ...

Core Viewpoint - The company proposes to spin off its subsidiary, Xiansheng Zaiming, for an independent listing of H-shares on the Hong Kong Stock Exchange, which has been confirmed by the exchange [1] Group 1: Spin-off Details - The spin-off of Xiansheng Zaiming's H-shares will be conducted in accordance with the application guidelines of the company [1] - The company plans to submit a listing application form (A1 form) to the Hong Kong Stock Exchange on January 9, 2026, for the approval of Xiansheng Zaiming's H-shares [1] - Following the proposed spin-off and listing, the company expects to retain over 50% ownership of Xiansheng Zaiming, which will remain a subsidiary [1] Group 2: Company Profile - Xiansheng Zaiming is a biopharmaceutical company at the forefront of global drug innovation, focusing on the research, development, and commercialization of innovative oncology drugs, excluding those related to cell therapy and gene diagnosis and treatment technologies [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考用途，並不構成收購、購買或認購任何證券之邀請或要約。 本公告並不構成在美國或任何其他倘無根據當地證券法律登記或符合資格即屬違 法的司法權區，要約提呈出售任何證券或邀請作出購買任何證券的要約。本公告 所述的證券將不會根據經修訂的 1933 年美國證券法（「證券法」）登記，亦不得在美 國作出要約或出售，惟根據證券法登記規定獲豁免或毋須遵守證券法的登記規定 進行的交易除外。於美國公開發售任何證券將須以招股章程形式作出。該招股章 程將載有關於提呈發售的公司以及其管理及財務報表的詳細資料。本公司無意在 美國進行任何證券的公開發售。 建議分拆 先聲再明醫藥股份有限公司 及在香港聯合交易所有限公司主板 獨立上市 建議分拆 本公司建議分拆本公司附屬公司先聲再明的H股在聯交所主板獨立上市。先聲 再明H股於聯交所主板獨立上市構成本公司根據第15項應用指引分拆先聲再 明。聯交所已確認本公司可進行建議分拆。 –1 ...

公司名稱: 先聲藥業集團有限公司 (於香港註冊成立的有限公司) 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 不適用 備註： 本公司乃於香港註冊成立。根據香港《公司條例》(第 622 章)，在香港註冊成立的公司沒有法定股本，因此並無"面值"的概念。 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02096 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 2,595,697,618 | | 0 | | 2,595,697,618 | | ...

从恒瑞离职四年多后，周云曙履新港股创新药企先声药业（2096.HK）。 据"江苏省肿瘤医院官方平台"2025年12月30日发布的消息，江苏省肿瘤医院（南京医科大学附属肿瘤医 院）"江苏省恶性肿瘤先进诊疗重点实验室"与先声药业"神经与肿瘤药物研发全国重点实验室"正式签署 战略合作协议。出席此次会议的嘉宾包括先声药业集团总裁周云曙。 公开资料显示，周云曙出生于1971年，高级工程师、博士，1995年毕业于中国药科大学，1995年起在江 苏恒瑞医药股份有限公司工作，历任发展部副部长、副总经理、总经理、董事，先后分管过研发、人力 资源、企业运营等业务，并于2014年开始主抓销售工作。 根据恒瑞医药2020年报资料，2003年至2020年1月，周云曙为公司董事、总经理，作为董事长、总经 理，其任职终止时间原本为2023年1月15日。但2021年7月9日，恒瑞医药公告称，董事会近日收到公司 董事长、总经理周云曙的辞职报告，周云曙因身体原因申请辞去公司董事长、总经理以及董事会专门委 员会相应职务，创始人孙飘扬回归。 2022年9月，中国证券监督管理委员会黑龙江监管局公布的一则行政处罚决定书显示，周云曙在2020年 涉嫌内幕 ...

Group 1 - The core point of the article is the appointment of Zhou Yunshu, a former senior executive at Heng Rui Medicine, as the president of Xiansheng Pharmaceutical Group, although the company later clarified that this information is not entirely accurate and no formal internal appointment has been made yet [1][3] - Zhou Yunshu has a long history with Heng Rui Medicine, having joined the company in 1995 and serving in various leadership roles, including general manager and chairman [4] - Zhou resigned from his positions at Heng Rui Medicine in July 2021 due to health reasons, and he was later involved in an insider trading case, resulting in a fine from the China Securities Regulatory Commission [4] Group 2 - Xiansheng Pharmaceutical is a well-established domestic pharmaceutical company focusing on areas such as neuroscience, oncology, and autoimmune diseases, and is also undergoing a transformation towards innovation [4] - In the first half of 2025, Xiansheng Pharmaceutical reported revenues of 3.585 billion yuan and a net profit attributable to shareholders of 604 million yuan, representing year-on-year growth of 15.14% and 32.20%, respectively [4] - The company's innovative drug business generated revenue of 2.776 billion yuan, a year-on-year increase of 26%, accounting for 77.4% of total revenue [4] - In 2025, Xiansheng Pharmaceutical announced three business development transactions, including licensing agreements for several drug candidates with AbbVie and other companies [5]